Aminotetraline activators of serotonin receptors
AssigneeATAI Life Sciences AG
InventorsGlenn Short, Robert B. Perni, Tanweer A. Khan
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (M-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof described herein. Also provided herein are pharmaceutical compositions comprising a compound Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.
Claims58
A compound of Formula (III):
- or a pharmaceutically acceptable salt thereof;
- wherein,
- R1 is independently methyl or C2-C6 fluoroalkyl;
- R2 and R3 are independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, halogen, CN, OR7, or —S(O)(Y)R6;
- Y is ═O or ═NH;
- R4 and R5 are independently H or C1-C6 fluoroalkyl;
- R6 and R7 are independently H, C1-C6 alkyl, or C1-C6 fluoroalkyl;
- and
- X is CH or N;
- wherein the compound is not 5,8-dimethoxy-6-methyl-1,2,3,4-tetrahydronaphthalen-2-amine;
- 5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine;
- 6-bromo-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine;
- 7-bromo-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine;
- 5,7,8-trimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine;
- or 5,6,8-trimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine.
A compound of Formula (IV):
- or a pharmaceutically acceptable salt thereof;
- wherein,
- R1 is independently H, C1-C6 alkyl, or C1-C6 fluoroalkyl;
- R3 is H, C1-C6 alkyl, C1-C6 fluoroalkyl, halogen, CN, OR7, or SR1;
- R4 and R5 are independently H, C1-C6 alkyl, or C1-C6 fluoroalkyl;
- R6 and R7 are independently H, C1-C6 alkyl, or C1-C6 fluoroalkyl;
- X is CH or N;
- Y is ═O or ═NH;
- m is 0, 1, or 3;
- and
- n is 0, 1, 2, or 3.
A compound selected from:
A method of treating a mental health disease or disorder, the method comprising administering a therapeutically effective amount of a compound of Formula (I), or a compound of Formula (II):
- (I)
- (II)
- or a pharmaceutically acceptable salt thereof;
- wherein,
- R1 is independently H, C1-C6 alkyl, or C1-C6 fluoroalkyl;
- R2, and R3, are independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, halogen, CN, OR1 S(O)NHR1R2, or SR1;
- R4 and R5 are independently H, C1-C6 alkyl, or C1-C6 fluoroalkyl;
- X is C or N;
- m is 0, 1, 2 or 3;
- and
- n is 0, 1, 2 or 3;
- provided that when n is 0, than X is N.
Dependencies are inferred from the claim text.